Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.33 |
| ▸ | F7 | P08709 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096713 | 1.00 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL10096709 | 0.97 | S1PR3 (0.37) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12995692 | 0.96 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL10096706 | 0.96 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL2886552 | 0.95 | HRH3 (0.37) | S1PR3NPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10096715 | 0.95 | MAPK8 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL10096708 | 0.94 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12994926 | 0.93 | NPC1 (0.34) | S1PR3NPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10096718 | 0.93 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12105902 | 0.93 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | S1PR3 1968/4885SOS1 4297/4885MAPK8 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.